Growth at a CAGR of approximately 9% in the Alpha Emitters Market during the forecast period| Major Vendors - IBA GROUP, LANTHEUS MEDICAL IMAGING, TRIAD ISOTOPES, SIEMENS HEALTHCARE, NTP RADIOISOTOPES, ALPHATAU, CARDINAL HEALTH, amongst others

Market Analysis:

US is the Largest Consumer Market
The market for alpha-emitters in the US is growing rapidly. The high-end research trend in the United States, coupled with high investments in healthcare research and abundant knowledge in cancer research, is the key factor propelling the growth of the market in the country. The government initiatives and trends toward the adoption of technologically-advanced products for healthcare are also fuelling the market growth.

Detailed Sample Copy of Updated Analysis @https://marketprognosis.com/sample-request/16677
Note: “If this link doesn’t work in Internet Explorer, kindly try pasting it in other browsers.”

IARC predicts - by 2030, the global burden is expected to grow to new cancer cases and cancer deaths simply due to a growth and aging of the population, leaving aside factors, like smoking, poor diet, physical inactivity, and fewer childbirths, in economically developing countries. Any other doubts about cancer being one of the major life threatening diseases in present time can be cleared by looking at the data presented by WHO. This global and extensive threat of cancer remains a major market driver for new cancer therapies involving alpha emitters and monoclonal antibody. Implementing cGMP guidelines, which are applicable for the drug industry, is both difficult and expensive. Hence, stringent regulatory framework, delays in transportation, and lack of transportation compliance, along with the fragile nature of radiopharmaceuticals with short half-life, are impeding the growth of the alpha emitters market.

Request Discount on this report @ https://marketprognosis.com/discount-request/16677
Note: “If this link doesn’t work in Internet Explorer, kindly try pasting it in other browsers.”

Market Segments:
Alpha Emitters Market is segmented by:
1. Type of Radionuclide: Terbium (Tb-149), Astatine (At-211), Bismuth (Bi-212), Actinium (Ac-225), Radium (Ra-223), Lead (Pb-212),Bismuth (Bi -213)
2. Medical Application: Glioma, Melanoma, Pancreatic Cancer, Ovarian Cancer, Thyroid, Bone Metastasis, Lymphoma, Endocrine Tumors, Others
3. Geography: North America, South America, Europe, Asia Pacific, Middle East & Africa

Key Developments
• December 2017: The US Department of Energy’s National Nuclear Security Administration (DOE/NNSA) and South African Nuclear Energy Corporation’s NTP Radioisotopes SOC Ltd (NTP) completed the conversion of their critical medical isotope molybdenum-99 (Mo-99) production process from highly-enriched uranium (HEU) to low-enriched uranium (LEU)
• November 2017: Actinium Pharmaceuticals launched the AWE Program aka Actinium Warhead Enabling Program to enable collaborations based on Its Actinium-225 Technology Platform

Enquiry Before Buying @ https://marketprognosis.com/enquiry/16677
Note: “If this link doesn’t work in Internet Explorer, kindly try pasting it in other browsers.”

About Market Prognosis
We at Market Prognosis believe in giving a crystal clear view of market dynamics for achieving success in today’s complex and competitive marketplace through our quantitative & qualitative research methods.
We help our clients identify the best market insights and analysis required for their business thus enabling them to take strategic and intelligent decision.
We believe in delivering actionable insights for your business growth and success.

Contact us:
ProgMarkPvt Ltd,
Thane - 421501
India.
Contact No: +1 973 241 5193
Email: sales@marketprognosis.com

This release was published on openPR.